While the absence of p52 results in faulty immune response, the lack of NF-κB inhibitory activity of p100 (Ishikawa et al., 1997) or overexpression of p52, lead to inflammatory diseases and cancer (Dejardin et al., 1995). Here, NFKB2 is linked to cancer.